24.29 -0.14 (-0.57%)
PRXL
| Trade PRXL now with |
Stock Details
Last Trade:24.29 Change:-0.14 (-0.57%) Prev Close:24.43 Open: 24.41 Days Range:24.03 – 24.69 52 Week Range: 15.26 - 27.91 Volume:181268 P/E: 40.48EPS:0.60
View AllRecent Alerts 02/10/12
Recent Alert on 02/01/12 at 6:43am
PAREXEL (PRXL) Enters Clinical Services Agreement with South Korea-Based AMC
PAREXEL (PRXL) Enters Clinical Services Agreement with South Korea-Based AMC
PAREXEL International Corporation (Nasdaq: PRXL), has entered into an agreement with ASAN Medical Center (AMC), based in Seoul, Korea. The alliance offers clinical trial sponsors based regionally and internationally with access to high quality... Read More
Recent Alert on 02/01/12 at 6:43am
PAREXEL (PRXL) Enters Clinical Services Agreement with South Korea-Based AMC
PAREXEL (PRXL) Enters Clinical Services Agreement with South Korea-Based AMC
Recent Alert on 01/31/12 at 1:51pm
Unusual 11 Midday Movers 01/31: (PRXL) (CTHR) (REE) (MSPD) Higher; (RSH) (PPO) (RTIX) Lower
Unusual 11 Midday Movers 01/31: (PRXL) (CTHR) (REE) (MSPD) Higher; (RSH) (PPO) (RTIX) Lower
Recent Alert on 01/31/12 at 10:12am
Morning Movers 01/31: (PRXL) (NBG) (MSPD) Higher; (RSH) (REXX) (MTH) Lower
Morning Movers 01/31: (PRXL) (NBG) (MSPD) Higher; (RSH) (REXX) (MTH) Lower
View AllRecent Press Releases
Press Release on 02/08/12 at 6:00am
PAREXEL Expands Global Clinical Logistics Capabilities to Support More Efficient Trial Execution
PAREXEL Expands Global Clinical Logistics Capabilities to Support More Efficient Trial Execution
Press Release on 02/06/12 at 6:00am
PAREXEL to Address Innovative Approaches to Late Stage Development at Summit for Clinical Ops Executives
PAREXEL to Address Innovative Approaches to Late Stage Development at Summit for Clinical Ops Executives
View AllRecent SEC Filings
SEC Filing on 02/06/12 at 1:37pm
Form 4 PAREXEL INTERNATIONAL For: Feb 03 Filed by: Brykman Kurt Arthur
Form 4 PAREXEL INTERNATIONAL For: Feb 03 Filed by: Brykman Kurt Arthur
View AllRecent Blog Posts
Blog Posts on 05/27/11 at 10:19am
Platform and Specialty Pharmaceutical Companies Could Strengthen in Face of Big Pharma's Patent Cliff
Platform and Specialty Pharmaceutical Companies Could Strengthen in Face of Big Pharma's Patent Cliff


